Sun Pharmaceutical Industries Ltd, a Rs. 27,200 crore pharma major has completed the acquisition of opiates business in Australia from GSK and commenced the integration. This acquisition fortifies Sun Pharma’s global position with two opiates manufacturing facilities in Port Fairy & Latrobe (both in Australia) complementing its current API manufacturing footprint globally.
Sun Pharma now offers a rich basket of opiates product line in addition to a large API portfolio and dosage formulations covering a broad range of chronic and acute prescription drugs. The acquisition also brings a specialised team to drive business growth.
With this acquisition Sun Pharma will able to expands its narcotics raw material (NRM) market share and will enhance opiate alkaloids portfolio and depth in global opiates market. Further, it will strengthen its strategic position in the global opiates business.